TScan Therapeutics Announces Presentations at Upcoming Industry Conferences
TScan Therapeutics, a biopharmaceutical company focused on the development of T-cell receptor (TCR)-engineered T cell therapies in oncology, today announced that management will present virtually at the following upcoming industry conferences:
H.C. Wainwright 22nd Annual Global Investment Conference
David Southwell, Chief Executive Officer, will present a company overview on September 14, 2020, at 12:30 p.m. Eastern Time
CAR-TCR Digital Week
Gavin MacBeath, Ph.D., Chief Scientific Officer, will present "TScan, a Whole Genome, Unbiased Approach to Cancer Target Discovery" on September 14, 2020, at 1:45 p.m. Eastern Time
American Society of Gene and Cell Therapy (ASGCT) COVID-19 Symposium
Dr. MacBeath will present the poster "Unbiased Genome-Wide Discovery Using TScan Reveals Shared Immunodominant CD8+ T Cell Epitopes in SARS-COV-2" in an oral session on September 16, 2020, at 5:00 p.m. Eastern Time
TCR-based Therapies Summit
Dr. MacBeath will lead the seminar "Expanding TCR Therapy by Identifying New Targets and TCRs from Patient TILs" on October 28, 2020, at 9:00 a.m. Eastern Time
About TScan Therapeutics
TScan discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors, and other serious diseases. Our proprietary, high-throughput platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of highly efficacious TCR-Ts with minimal off-target effects. Lead program TSC-100 is expected to enter clinical development for liquid cancers in 2021, and the Company is advancing additional TCR-Ts for solid cancers. TScan was co-founded by Chair Christoph Westphal (Partner, Longwood Fund) based on pioneering research from the Elledge Lab at Brigham and Women's Hospital. The Company has raised over $80 million to date from leading strategic collaborators and investors including Longwood Fund, Novartis Institutes for Biomedical Research, Astellas Venture Management, Novartis Venture Fund, Bessemer Venture Partners, GV, 6 Dimensions Capital, and Pitango Venture Capital.
Vaccines are one of the most significant public health achievements in modern history, playing a vital role in helping to prevent certain infectious diseases and protect communities across the globe.Unfortunately, the COVID-19 pandemic brought forth...
Coveo , a leading provider of enterprise AI Search, Recommendations and Generative Experience platforms that enable individualized, connected, and trusted digital experiences at scale with unified relevance, today announced two new GenAI business...
Cove Capital Investments reviews and analyzes nearly every type of asset class available for Delaware Statutory Trust investors. This list of potential DST property asset classes includes government leased buildings, self-storage facilities,...
The "United States Self-Monitoring Blood Glucose Devices Market Growth, Share, Size, Trends, Analysis and Forecast (2024 - 2032)" report has been added to ResearchAndMarkets.com's offering.
The U.S. Self-Monitoring Blood Glucose Devices market size...
Arch Insurance North America (Arch), a provider of specialized insurance and risk management solutions, today unveiled its latest products available through the Arch APEX? digital platform. Participant Accident coverage is now available for child...